What are ADC's

Our services

ADC Review
is made possible by:

NCT00017589 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia (NCT00017589)

Trial Description
Monoclonal antibodies, including antibody-drug conjugates such as gemtuzumab ozogamicin, can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Oblimersen may help gemtuzumab ozogamicin kill more cancer cells by making cancer cells more sensitive to the drug.

Phase II trial to study the effectiveness of combining oblimersen and gemtuzumab ozogamicin in treating older patients who have relapsed acute myeloid leukemia.

This trial is sponsored by Genta Inc.*/ National Cancer Institute (NCI). [1]

Study Data

  • Condition: Leukemia
  • Interventions:
  • Phase: II
  • Start: December 2000
  • Completion: May 2006
  • Last verified: April 2003

Study Schematic

(Coming soon)

Click here to Return to Drug map

* In August 2012 Genta Inc. filed for bankruptcy.

**Genasense® (oblimersen sodium) is a compound that blocks production of the Bcl-2 protein. By first lowering levels of Bcl-2, it is possible that chemotherapy drugs may work more effectively as a cancer treatment. Genasense® may also directly kill CLL cells.

Last Editorial review: July 22, 2015
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar